Mild-to-moderate depression supplement protocol — what the evidence supports as adjunctive

Bottom Line

These supplements are adjunctive: they can take the edge off mild-to-moderate symptoms and complement an antidepressant, but they don’t replace therapy or medication for moderate-to-severe depression and have no role in suicidal or psychotic depression. The best-evidenced options are genuinely strong for non-prescription agents — standardised saffron extract was non-inferior to fluoxetine 20 mg in mild-to-moderate depression (a large effect for a supplement), and form and dose matter for the others, with EPA-dominant omega-3 (at least 1 g of EPA) and SAMe also carrying real trial support. Several of these are serotonergic, so saffron, SAMe and similar agents need prescriber coordination if you take an SSRI, SNRI, MAOI or tramadol, and you should never stop an antidepressant abruptly. If you are having thoughts of suicide or self-harm, contact a crisis line (988 in the US) or emergency care now — supplements do not treat that.

If you're having thoughts of suicide or self-harm, this is not the right resource. Reach a crisis line (988 in the US, 111 / local equivalents elsewhere), an emergency department, or a trusted clinician now. Supplements do not treat suicidality. Therapy and medication do, often quickly. Also: do not stop a prescribed antidepressant abruptly to switch to a supplement protocol — SSRI / SNRI discontinuation syndrome is real and can be severe. Coordinate any changes with the prescriber.

The role of supplements in depression

The evidence base for non-supplement first-line treatments is large: cognitive behavioural therapy, interpersonal therapy, and behavioural activation have effect sizes comparable to antidepressants for mild-to-moderate presentations. Exercise — particularly aerobic exercise at 3+ sessions per week — has effect sizes in the d=0.4–0.6 range, on par with many medications. Sleep regulation, alcohol reduction, and light exposure each meaningfully shift mood. The supplements below sit alongside these levers and are most useful when (a) you are working with a clinician, (b) symptoms are in the mild-to-moderate range, and (c) you've ruled out the medical mimics (hypothyroidism, anaemia, B12 deficiency, undiagnosed sleep apnoea, untreated chronic pain) that present as depression but require different treatment.

Top supplements with strong evidence

Tier 1 evidence · Head-to-head with SSRIs in mild-moderate

Saffron (Crocus sativus) extract

28–30 mg/day standardised extract (crocins/safranal), split twice daily

The Lopresti 2014 meta-analysis (6 RCTs) and subsequent updates have shown standardised saffron extract is more effective than placebo and non-inferior to fluoxetine 20 mg in mild-to-moderate MDD. Effect sizes are large for a non-prescription intervention (Hedges' g ≈ 0.99 vs placebo). Mechanism appears to involve serotonin reuptake inhibition plus antioxidant and anti-inflammatory action. The most-studied product is affron® (Crocus sativus extract standardised to ≥3.5% lepticrosalides), but several reputable extracts produce comparable results. Caution: serotonin syndrome theoretical risk when combined with SSRIs, MAOIs, or tramadol — coordinate with prescriber.

Tier 1 evidence · EPA-dominant, not generic fish oil

Omega-3 (EPA-dominant)

1–2 g/day EPA, with EPA:DHA ratio ≥2:1

The Liao 2019 meta-analysis (26 RCTs, n=2,160) showed EPA-predominant omega-3 formulations significantly reduced depressive symptoms vs placebo. Effect was concentrated in formulations with ≥60% EPA and total EPA dose ≥1 g/day. DHA-dominant formulations and combined low-EPA mixes were not effective. Mechanism: anti-inflammatory eicosanoid shifting plus membrane fluidity effects on neurotransmission. This is one of the cleanest examples of "form and dose matter": the supplement aisle is full of fish oil that wouldn't reach the EPA dose used in trials.

Tier 1 evidence · Including head-to-head with escitalopram

S-adenosyl-L-methionine (SAMe)

800–1,600 mg/day, on empty stomach, split twice daily

The Mischoulon 2014 12-week RCT compared SAMe 1,600–3,200 mg/day to escitalopram 10–20 mg/day in MDD and found no significant difference in response rates. Multiple earlier trials showed SAMe outperforms placebo and adds to SSRI response in partial responders (Papakostas 2010 RCT — SAMe 800 mg twice daily added to SSRI improved response in non-responders). Mechanism: methyl donor for monoamine synthesis. Caution: theoretical hypomania induction risk in bipolar — screen for bipolar history before recommending. Use enteric-coated stabilised tablets; SAMe degrades quickly on exposure to air and moisture.

Tier 1 evidence · For SSRI partial-responders specifically

L-methylfolate (active folate)

7.5–15 mg/day L-methylfolate (5-MTHF), as adjunct

The Papakostas 2012 trial of L-methylfolate 15 mg/day as adjunct to SSRI in patients who had partial response showed significant improvement vs placebo. Folate is a cofactor in monoamine synthesis (via tetrahydrobiopterin regeneration). L-methylfolate (the bioactive form) bypasses MTHFR polymorphisms that limit conversion of synthetic folic acid. Specifically useful for SSRI partial-responders, people with low or borderline folate, and people with confirmed MTHFR variants. Use the bioactive 5-MTHF form, not synthetic folic acid.

Tier 2 evidence · Replete deficiency, not pharma dosing

Vitamin D3 (when deficient)

1,000–2,000 IU/day to reach serum 25(OH)D 30–50 ng/mL

The relationship between vitamin D status and depression is debated. The Kjaergaard 2012 trial in deficient depressed adults found benefit; the BIODEP and VITAL-DEP analyses in replete adults did not. The reasonable read: vitamin D is not an antidepressant per se, but correcting frank deficiency is plausibly mood-supportive and addresses a common coexisting issue. Test 25(OH)D, replete deficiency, don't megadose unselected. The Anglin 2013 meta-analysis showed lower vitamin D levels are consistently associated with depression, though causality is unclear.

Tier 2 evidence · Modest adjunctive effect

Curcumin (bioavailable form)

500–1,000 mg/day bioavailable curcumin, split twice daily

The Ng 2017 meta-analysis (6 RCTs, n=377) showed curcumin reduced depressive symptoms vs placebo, with larger effects in middle-aged adults and at doses ≥500 mg/day for 6+ weeks. Mechanism: BDNF upregulation, anti-inflammatory, monoamine modulation. Effect size is modest (Hedges' g ≈ 0.34). Use a bioavailable formulation (phytosome, liposomal, or piperine-co-formulated) — plain curcumin powder has <1% absorption. Reasonable add-on with low risk profile.

Conditional / situational supplements

Conditional · Zinc (especially in low-zinc populations)

The Lai 2012 meta-analysis suggested zinc as adjunct to antidepressants modestly improves response. Zinc deficiency is reasonably common in restrictive eating patterns, post-bariatric, or chronic GI disease. Test serum zinc if dietary history suggests deficiency; supplement zinc 15–30 mg/day for 8–12 weeks. Not a primary intervention in adequate-intake populations.

Conditional · Methylcobalamin (B12) — replete deficiency

B12 deficiency is a depression mimic — fatigue, low mood, cognitive slowing all overlap. The clinical move is to test serum B12 (and methylmalonic acid if borderline) before assuming psychiatric aetiology, especially in vegans, older adults, post-bariatric patients, and long-term metformin or PPI users. Replete with methylcobalamin 1,000 µg/day. Don't supplement reflexively in replete adults — the trial evidence for B12 as a primary antidepressant in non-deficient people is weak.

Conditional · St John's wort (Hypericum perforatum) — mild only, drug-interaction caveats

The Linde 2008 Cochrane review found St John's wort comparable to standard antidepressants in mild-to-moderate depression with fewer side effects. But: St John's wort is a potent inducer of CYP3A4, CYP2C9, P-glycoprotein, and other drug-metabolism pathways. It significantly reduces levels of oral contraceptives (causing pill failure), warfarin, DOACs, calcineurin inhibitors, many antiretrovirals, statins, and chemotherapy. Serotonin syndrome risk with SSRIs/SNRIs/triptans/tramadol. Use only when no other prescription drugs are in play, and only with prescriber awareness.

What to skip

Medication considerations

The interaction layer is the highest-stakes part of depression supplementation, because the most-prescribed antidepressants act on serotonin, and several effective supplements also do.

The lifestyle bedrock

The single highest-leverage non-medication intervention in mild-to-moderate depression is exercise. Cooney 2013 Cochrane and subsequent meta-analyses (Schuch 2016) show aerobic exercise has effect sizes comparable to antidepressants for mild-to-moderate presentations, with no dependence, low cost, and a cardiometabolic dividend. Sleep regulation matters comparably — chronic insufficient sleep both causes and maintains depressive symptoms; the bidirectional loop with depression is one of the strongest in psychiatric epidemiology. Reduced alcohol intake, daily outdoor light exposure (especially in winter at high latitudes), and structured social engagement all have evidence bases. Therapy — particularly CBT, behavioural activation, and IPT — has effect sizes equal to or exceeding pharmacotherapy in mild-to-moderate MDD, with durable benefit after treatment ends. Supplements augment all of this. They do not substitute for any of it.

Practical layered start. (1) Confirm the diagnosis with a clinician and rule out medical mimics (thyroid panel, B12, iron, vitamin D, sleep apnoea screen). (2) Lifestyle base: aerobic exercise 3–5×/week, sleep window ≥7 hours, alcohol <7 drinks/week, daily outdoor light. (3) Therapy referral — CBT or IPT — if not already in place. (4) For mild-to-moderate symptoms with no prescription medication: trial saffron 30 mg/day for 6–8 weeks, or EPA-dominant omega-3 1 g/day, or SAMe 800–1,600 mg/day. Pick one, give it 6 weeks. (5) If on an SSRI with partial response: add L-methylfolate 7.5–15 mg/day or EPA omega-3 — both have RCT evidence as SSRI adjuncts. (6) Replete vitamin D, B12, iron and zinc if deficient. (7) Reassess at 8 weeks. If symptoms worsen or do not improve, escalate clinical care — supplements are not a substitute for adequate treatment of moderate-to-severe depression.

Sources

Supplement details

Related conditions